Our findings of the primary endpoint outcome demonstrated that COVID-19 patients with elevated cTnT levels had a higher prevalence of baseline cardiovascular conditions, such as atrial fibrillation, myocarditis, and heart failure. This evidence concerns the gene TNNT2 and atrial fibrillation.